MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to financial losses for investors [2]. - The firm is encouraging investors who suffered losses to contact them for further discussion on their legal rights and options [1][3]. Recent Events - On September 29, 2025, MoonLake filed a current report with the SEC, revealing that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a stock price decline of 89.9% on the same day [6].